OptimizeRx (OPRX) Cash & Equivalents (2010 - 2026)

OptimizeRx (OPRX) has 17 years of Cash & Equivalents data on file, last reported at $20.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 21.7% year-over-year to $20.2 million; the trailing twelve-month figure through Mar 2026 stood at $20.2 million (up 21.7% YoY), and the FY2025 full-year result was $23.4 million, up 74.63% from the prior year.
• Cash & Equivalents retreated to $20.2 million in Q1 2026, from $23.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $89.0 million in Q1 2022 to a low of $9.8 million in Q2 2023.
• A 5-year average of $26.0 million and a median of $16.6 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 88.78% in 2023 and jumped 74.63% in 2025, its largest moves.
• Tracing OPRX's Cash & Equivalents over 5 years: stood at $18.2 million in 2022, then fell by 23.93% to $13.9 million in 2023, then decreased by 3.41% to $13.4 million in 2024, then jumped by 74.63% to $23.4 million in 2025, then dropped by 13.68% to $20.2 million in 2026.
• Business Quant data shows OPRX's Cash & Equivalents at $20.2 million in Q1 2026, $23.4 million in Q4 2025, and $19.5 million in Q3 2025.